Researcher

Peter Attia

Last updated Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 2 min read

Background

Peter Attia trained as a mechanical engineer at Queen’s University, then earned an MD at Stanford and completed general-surgery residency at Johns Hopkins under the late John Cameron. He spent years at McKinsey doing risk analysis before pivoting full-time to preventive medicine, founding a private longevity-medicine practice.

Lines of work

Not a basic-science researcher. Attia’s influence is as a translator and applied clinician focused on:

Exercise prescription

The zone-2 + VO₂max + strength + stability framework popularised in Outlive. He argues exercise is the single highest-leverage longevity intervention and prescribes higher volumes of resistance and stability work than typical guidelines.

Lipidology

Uses apoB as the operational measure of atherogenic particle burden. Aggressive early initiation of LDL/apoB lowering in adults with elevated lifetime cardiovascular risk — well below the ages at which most clinical guidelines start treatment.

Cancer screening

Advocates earlier and more sensitive screening than current guidelines, including discussion of Galleri, low-dose CT, whole-body MRI, and colonoscopy at younger ages. Honest about the cost, anxiety, and false-positive trade-offs.

Nutrition and protein

Emphasises protein adequacy (1.6–2.2 g/kg/day for many adults) to preserve muscle through the lifespan. Less doctrinaire about specific dietary patterns than other public voices.

Off-label longevity-drug discussion

Discusses rapamycin (low intermittent dosing), metformin (now more cautious after exercise-interaction signals), GLP-1 agonists with appropriate framing. Generally more reserved than longevity-adjacent influencers about specific drug recommendations.

Public profile

Outlive (2023) is the most widely-read recent popular longevity-medicine book. The Drive podcast publishes ~3-hour technical interviews with researchers and clinicians; one of the more substantive longevity-information channels available.

What he gets right (and where to read critically)

Attia is unusually rigorous for the public-facing longevity-medicine space. Strengths: lipidology and exercise prescription are evidence-based; he openly updates his views (e.g. walking back his earlier metformin enthusiasm). What to read critically: aggressive screening recommendations have real cost and false-positive harms; off-label drug discussion requires individual clinician input; the "Medicine 3.0" framing is more aspirational than scientifically defined.

Affiliations & disclosures

Practises medicine privately. Runs a paid Early Medicine podcast membership. Product affiliations, supplement-brand investments, and financial relationships are disclosed on his site. No major direct biotech-equity conflicts comparable to academic-founder figures.

References

Attia, P. Outlive: The Science and Art of Longevity. Harmony Books (2023).